MetAP2 Inhibitor Polymer Conjugates for Angiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current polymer drug conjugates, such as TNP-470, face challenges with dose-limiting neurotoxicity, short half-life, and formulation difficulties due to their hydrophobic nature, limiting their therapeutic efficacy in treating cancers like lung, cervical, ovarian, and breast cancers.
Innovation Solution
Development of novel polymer conjugates with a molecular weight of less than 60 kDa, incorporating a MetAP2 inhibitor moiety linked via a self-immolating linker, which releases the inhibitor to effectively target and inhibit methionine aminopeptidase-2, thereby blocking angiogenesis and tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TNP-470 is used to inhibit MetAP2 and block angiogenesis, then therapeutic activity against cancers is improved, but dose-limiting neurotoxicity increases
Solution Approach 1:
The patent segments the drug delivery system by separating the hydrophobic MetAP2 inhibitor (TNP-470 or carbamoylfumagillol) from the aqueous environment through conjugation to polymeric carriers. This segmentation allows the drug to be delivered in a controlled manner, reducing systemic toxicity while maintaining therapeutic activity at the tumor site.
Solution Approach 2:
The patent introduces polymeric intermediaries (amphipathic block copolymers, dendrimers, and micelles) that mediate between the hydrophobic drug and the aqueous biological environment. These intermediaries solubilize the drug, control its release, and reduce off-target toxicity including neurotoxicity, while delivering the therapeutic agent to tumor tissues.
2Reliability
If TNP-470 is administered to achieve therapeutic effects, then tumor growth inhibition is improved, but half-life is shortened requiring extended administration
Solution Approach 1:
The patent applies preliminary action by pre-conjugating the MetAP2 inhibitor to polymeric carriers with controlled degradation rates. The polymeric structure is designed to maintain drug stability during circulation and then undergo controlled degradation or degradation-triggered release at the target site, extending the effective duration of action and enabling sustained tumor growth inhibition.
3Reliability
If carbamoylfumagillol and derivatives are used as MetAP2 inhibitors, then antiangiogenic activity is improved, but formulation difficulty increases due to hydrophobicity
Solution Approach 1:
The patent creates composite materials by conjugating hydrophobic MetAP2 inhibitors (carbamoylfumagillol and derivatives) to amphipathic polymeric carriers. The composite structure combines hydrophobic drug molecules with hydrophilic polymer chains, creating water-soluble conjugates that are easy to formulate and administer while maintaining potent antiangiogenic activity.
4Reliability
If polymer conjugates are used to reduce toxicity, then therapeutic index is improved, but molecular weight increases affecting pharmacokinetics
Solution Approach 1:
The patent systematically varies key parameters of the polymeric carriers including molecular weight, block composition, degree of drug conjugation, and structural architecture (linear, branched, dendritic). By optimizing these parameters, the patent achieves formulations that reduce toxicity (improving therapeutic index) while maintaining favorable pharmacokinetic properties through controlled size and degradation characteristics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymer conjugates demonstrate enhanced therapeutic activity with reduced toxicity and improved pharmacokinetics, showing significant weight-bearing capacity and tumor size reduction in preclinical models, offering a more effective treatment for various cancers with lower doses compared to traditional small molecules.
Implementation Method 1
incorporating a MetAP2 inhibitor moiety linked via a self-immolating linker, which releases the inhibitor
Data Source
AI summary
One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor.